VIRX - Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
PR Newswire
SAN DIEGO , April 8, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20 th Annual Needham Virtual Healthcare Conference taking place April 12-15, 2021 . The Company will also participate in one-on-one investor meetings at the conference.
Details on the presentation can be found below.
| Date: |
| Wednesday, April 14, 2021 |
| Time: |
| 3:45 PM ET |
| Format: |
| Corporate presentation |
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
For additional information please visit www.viracta.com .
| Investor Relations Contact: |
| Company Contact: |
| Joyce Allaire |
| Dan Chevallard |
| LifeSci Advisors |
| Chief Operating Officer and Chief Financial Officer |
| (212) 915-2569 |
| (858) 771-4193 |
SOURCE Viracta
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.